Blog

DEEP RESEARCH · Hanmi Pharm / Efpeglenatide

Hanmi Pharm Efpeglenatide Phase 3: First Validation of the Obesity Pipeline

A 40-week top-line readout interpreted through efficacy, competitive positioning, manufacturing, and follow-on pipeline value.

Date: 2025-10-27 · Pharma/obesity therapeutics analysis · Naver Blog

You are responsible for your own investment decisions. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

The 40-week Phase 3 result supports domestic commercialization potential. But versus Wegovy and Zepbound, global best-in-class efficacy remains uncertain. The investment relevance is less the single drug and more validation of LAPSCOVERY and the H.O.P. obesity pipeline.

The source begins with the author's caution that few investors would buy Hanmi Pharm for this drug alone, so the post is primarily a record of the analysis. The prior analysis is linked here: Hanmi Pharm overview.

Thumbnail for the prior Hanmi Pharm analysis link

1. Phase 3 Top-Line Result: Co-Primary Endpoints Met

Official fact: The study is described as a multicenter, randomized, double-blind, placebo-controlled trial in 448 adults with obesity and without diabetes. The full analysis set is presented as 446 patients.

EndpointEfpeglenatidePlaceboDifference/statistics
Patients with at least 5% weight loss79.42%14.49%64.93 percentage points, p<0.0001
Mean weight change at week 40-9.75%-0.95%LSmean difference -8.13%, 95% CI -9.43% to -6.82%, p<0.0001

Interpretation: Both the 5% responder rate and average weight reduction show clear superiority to placebo. For Korean approval and early commercialization, the data are meaningful.

2. Duration Limitation: Week 40 Versus Week 64

Official fact: The source states that Wegovy's STEP 1 and Zepbound's SURMOUNT-1 pivotal trials ran 68 and 72 weeks, respectively. Efpeglenatide's data are from week 40, with a 24-week extension expected to produce total 64-week data.

Why Timing Matters in Efficacy ComparisonIntermediate results should not be treated as final results
Week 40Efpeglenatide -9.75%
Week 64Extension readout
Week 68Wegovy STEP 1 comparison axis
Week 72Zepbound SURMOUNT-1 comparison axis
The current readout is a successful interim result; global competitiveness depends more on the 64-week data.

Interpretation: GLP-1-class weight loss can continue after week 40, so the current number should not be treated as final efficacy. The key question is whether week 64 moves into the low-to-mid teens.

3. Competition: Domestic Opportunity, Global Limits

Domestic

Korean market potential

The placebo-adjusted efficacy is clear enough to support a domestic launch and early prescription base.

Global

Efficacy gap

The source notes that Zepbound reset expectations with weight loss above 20%. Efpeglenatide is unlikely to become global best-in-class on efficacy alone.

Supply

Manufacturing asset

In a global GLP-1 shortage, cGMP-certified internal manufacturing is presented as a strategic asset for stable domestic supply.

4. Real Investment Point: LAPSCOVERY and H.O.P.

Official fact: The source treats the Phase 3 success as late-stage validation of Hanmi's long-acting LAPSCOVERY™ platform and as the first step in H.O.P., the Hanmi Obesity Pipeline.

Hanmi Obesity Pipeline SequencingPlatform validation matters more than a single asset
EfpeglenatideDomestic revenue and platform proof
HM15275Triple agonist, next-generation efficacy option
HM17321Muscle preservation/gain mechanism
Oral GLP-1Convenience option
Efpeglenatide is best viewed as the first validation that can lower perceived risk for later assets.

Interpretation: Long-term enterprise value is more likely to be driven by HM15275 and HM17321 clinical success than by efpeglenatide revenue alone.

5. Risks and Catalysts

CategoryContent
Main risksClear efficacy gap in 64-week data, fast innovation in obesity drugs, failure to secure global partners
MitigantsManufacturing control, multiple shots on goal in H.O.P., continuing R&D investment cited at 13-15% of revenue
Near-term catalysts64-week final data and global commercialization partnership
Long-term catalystsPositive Phase 2 data for HM15275 and Phase 1 data for HM17321

Interpretation: The source states a final 'Buy' view. I preserve that as the original author's conclusion, not as a recommendation in this report.

Sources

Naver original